Medical history and COVID-19 associated symptoms
| No liver damage (LS <5 kPa) n=20 | Liver damage (LS >5 kPa) n=12 | P value | |
| Age | 69.9 (±16.2) | 73.5 (±13.9) | 0.76 |
| Sex (male) | 35% | 50% | 0.82 |
| Smoker | 25% | 42% | 0.66 |
| Allergies | 5% | 8% | 0.32 |
| Malignant disease | 15% | 16% | 0.93 |
| Hypertension | 35% | 41% | 0.54 |
| Diabetes | 10% | 16% | 0.75 |
| Chronic liver disease | 10%*† | 8%* | 0.34 |
| Chronic heart disease | 30%ठ| 8%ठ| 0.06 |
| Pregnancy | 0% | 0% | – |
| COPD | 5% | 8% | 0.33 |
| Immunosuppression | 5% | 8% | 0.22 |
| Fever (≥37.3°C) | 70% | 83% | 0.94 |
| Dyspnoea | 60% | 75% | 0.52 |
| Cough | 80% | 92% | 0.23 |
| Sputum | 35% | 58% | 0.81 |
| Haemoptysis | 0% | 0% | -- |
| Sore throat | 70% | 75% | 0.92 |
| Nasal obstruction | 55% | 75% | 0.74 |
| Muscle ache | 20% | 42% | 0.70 |
| Fatigue | 60% | 92% | 0.31 |
| Shortness of breath | 50% | 67% | 0.93 |
| Nausea | 60% | 83% | 0.85 |
| Vomiting | 0% | 60% | 0.001* |
| Diarrhoea | 5% | 75% | 0.02* |
| X-ray (opacities) | 30% | 90% | 0.02* |
| Antibiotic therapy | 10% | 8% | 0.85 |
| Antiviral therapy | 5% | 8% | 0.31 |
bold indicates statistical singificant.
*MAFLD (n=2).
†Chronic hepatitis C infection after successful antiviral therapy (n=1).
‡Chronic heart failure (n=3).
§Coronary heart disease (n=4).
COPD, chronic obstructive pulmonary disease; LS, liver stiffness; MAFLD, metabolic associated fatty liver disease.